Molecular Weight:   | 174.15 |
Volume:   | 185.559 |
LogP:   | -2.024 |
LogD:   | -1.22 |
LogS:   | 0.299 |
# Rotatable Bonds:   | 2 |
TPSA:   | 29.46 |
# H-Bond Aceptor:   | 3 |
# H-Bond Donor:   | 1 |
# Rings:   | 1 |
# Heavy Atoms:   | 3 |
QED Drug-Likeness Score:   | 0.607 |
Synthetic Accessibility Score:   | 4.218 |
Fsp3:   | 1.0 |
Lipinski Rule-of-5:   | Accepted |
Pfizer Rule:   | Accepted |
GSK Rule:   | Accepted |
BMS Rule:   | 0 |
Golden Triangle Rule:   | Rejected |
Chelating Alert:   | 0 |
PAINS Alert:   | 0 |
Caco-2 Permeability:   | -5.567 |
MDCK Permeability:   | 0.0003310595056973398 |
Pgp-inhibitor:   | 0.0 |
Pgp-substrate:   | 0.473 |
Human Intestinal Absorption (HIA):   | 0.806 |
20% Bioavailability (F20%):   | 0.977 |
30% Bioavailability (F30%):   | 0.991 |
Blood-Brain-Barrier Penetration (BBB):   | 0.209 |
Plasma Protein Binding (PPB):   | 12.359308242797852% |
Volume Distribution (VD):   | 0.747 |
Pgp-substrate:   | 86.8924789428711% |
CYP1A2-inhibitor:   | 0.009 |
CYP1A2-substrate:   | 0.675 |
CYP2C19-inhibitor:   | 0.017 |
CYP2C19-substrate:   | 0.058 |
CYP2C9-inhibitor:   | 0.001 |
CYP2C9-substrate:   | 0.132 |
CYP2D6-inhibitor:   | 0.001 |
CYP2D6-substrate:   | 0.869 |
CYP3A4-inhibitor:   | 0.003 |
CYP3A4-substrate:   | 0.064 |
Clearance (CL):   | 4.32 |
Half-life (T1/2):   | 0.923 |
hERG Blockers:   | 0.012 |
Human Hepatotoxicity (H-HT):   | 0.221 |
Drug-inuced Liver Injury (DILI):   | 0.006 |
AMES Toxicity:   | 0.027 |
Rat Oral Acute Toxicity:   | 0.437 |
Maximum Recommended Daily Dose:   | 0.893 |
Skin Sensitization:   | 0.255 |
Carcinogencity:   | 0.284 |
Eye Corrosion:   | 0.323 |
Eye Irritation:   | 0.493 |
Respiratory Toxicity:   | 0.917 |
Natural Product ID:   | NPC293551 |
Common Name*:   | Muscarine |
IUPAC Name:   | [(2S,4R,5S)-4-hydroxy-5-methyloxolan-2-yl]methyl-trimethylazanium |
Synonyms:   | L-(+)-muscarine; Muscarin |
Standard InCHIKey:   | UQOFGTXDASPNLL-XHNCKOQMSA-N |
Standard InCHI:   | InChI=1S/C9H20NO2/c1-7-9(11)5-8(12-7)6-10(2,3)4/h7-9,11H,5-6H2,1-4H3/q+1/t7-,8-,9+/m0/s1 |
SMILES:   | O[C@@H]1C[C@H](O[C@H]1C)C[N+](C)(C)C |
Synthetic Gene Cluster:   | n.a. |
ChEMBL Identifier:   | CHEMBL12587 |
PubChem CID:   |
9308 |
Chemical Classification**:   |
|
*Note: the InCHIKey will be temporarily assigned as the "Common Name" if no IUPAC name or alternative short name is available.
**Note: the Chemical Classification was calculated by NPClassifier Version 1.5. Reference: PMID:34662515.
Organism ID | Organism Name | Taxonomy Level | Family | SuperKingdom | Isolation Part | Collection Location | Collection Time | Reference |
---|---|---|---|---|---|---|---|---|
NPO7513 | Cannabis sativa | Species | Cannabaceae | Eukaryota | n.a. | n.a. | n.a. | DOI[10.1021/np50031a011] |
NPO7513 | Cannabis sativa | Species | Cannabaceae | Eukaryota | n.a. | n.a. | n.a. |
PMID[18303850] |
NPO7513 | Cannabis sativa | Species | Cannabaceae | Eukaryota | n.a. | n.a. | n.a. |
PMID[18681481] |
NPO7513 | Cannabis sativa | Species | Cannabaceae | Eukaryota | n.a. | n.a. | n.a. |
PMID[19344127] |
NPO7513 | Cannabis sativa | Species | Cannabaceae | Eukaryota | n.a. | aerial part | n.a. |
PMID[21902175] |
NPO7513 | Cannabis sativa | Species | Cannabaceae | Eukaryota | n.a. | n.a. | n.a. |
PMID[26000707] |
NPO7513 | Cannabis sativa | Species | Cannabaceae | Eukaryota | n.a. | n.a. | n.a. |
PMID[32880179] |
NPO7513 | Cannabis sativa | Species | Cannabaceae | Eukaryota | n.a. | n.a. | n.a. | Database[Article] |
NPO7513 | Cannabis sativa | Species | Cannabaceae | Eukaryota | n.a. | n.a. | n.a. | Database[HerDing] |
NPO7513 | Cannabis sativa | Species | Cannabaceae | Eukaryota | n.a. | n.a. | n.a. | Database[TCMID] |
NPO7513 | Cannabis sativa | Species | Cannabaceae | Eukaryota | n.a. | n.a. | n.a. | Database[TCM_Taiwan] |
NPO7513 | Cannabis sativa | Species | Cannabaceae | Eukaryota | n.a. | n.a. | n.a. | Database[TM-MC] |
NPO7513 | Cannabis sativa | Species | Cannabaceae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
☑ Note for Reference:
In addition to directly collecting NP source organism data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated them from below databases:
☉ UNPD: Universal Natural Products Database [PMID: 23638153].
☉ StreptomeDB: a database of streptomycetes natural products [PMID: 33051671].
☉ TM-MC: a database of medicinal materials and chemical compounds in Northeast Asian traditional medicine [PMID: 26156871].
☉ TCM@Taiwan: a Traditional Chinese Medicine database [PMID: 21253603].
☉ TCMID: a Traditional Chinese Medicine database [PMID: 29106634].
☉ TCMSP: The traditional Chinese medicine systems pharmacology database and analysis platform [PMID: 24735618].
☉ HerDing: a herb recommendation system to treat diseases using genes and chemicals [PMID: 26980517].
☉ MetaboLights: a metabolomics database [PMID: 27010336].
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
Organism ID | NP ID | Organism Material Preparation | Organism Part | NP Quantity (Standard) | NP Quantity (Minimum) | NP Quantity (Maximum) | Quantity Unit | Reference |
---|
☑ Note for Reference:
In addition to directly collecting NP quantitative data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated NP quantitative records for specific NP domains (e.g., NPS from foods or herbs) from domain-specific databases. These databases include:
☉ DUKE: Dr. Duke's Phytochemical and Ethnobotanical Databases.
☉ PHENOL EXPLORER: is the first comprehensive database on polyphenol content in foods [PMID: 24103452], its homepage can be accessed at here.
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT420 | Individual Protein | Muscarinic acetylcholine receptor M3 | Cavia porcellus | pD2 | = | 6.8 | n.a. | PMID[549494] |
NPT420 | Individual Protein | Muscarinic acetylcholine receptor M3 | Cavia porcellus | Efficiency | = | 100.0 | % | PMID[549494] |
NPT262 | Individual Protein | Muscarinic acetylcholine receptor M1 | Homo sapiens | Inhibition | = | 2.0 | % | PMID[549495] |
NPT262 | Individual Protein | Muscarinic acetylcholine receptor M1 | Homo sapiens | Ki | = | 56.0 | nM | PMID[549495] |
NPT263 | Individual Protein | Muscarinic acetylcholine receptor M2 | Homo sapiens | Ki | = | 25.0 | nM | PMID[549495] |
NPT263 | Individual Protein | Muscarinic acetylcholine receptor M2 | Homo sapiens | Ki | = | 72.0 | nM | PMID[549495] |
NPT264 | Individual Protein | Muscarinic acetylcholine receptor M3 | Homo sapiens | Inhibition | = | 28.0 | % | PMID[549495] |
NPT265 | Individual Protein | Muscarinic acetylcholine receptor M4 | Homo sapiens | Ki | = | 1400.0 | nM | PMID[549495] |
NPT265 | Individual Protein | Muscarinic acetylcholine receptor M4 | Homo sapiens | Ki | = | 23.0 | nM | PMID[549495] |
NPT1301 | Individual Protein | Muscarinic acetylcholine receptor M2 | Rattus norvegicus | K app | = | 2.3 | uM | PMID[549497] |
NPT263 | Individual Protein | Muscarinic acetylcholine receptor M2 | Homo sapiens | PD2 | = | 6.69 | n.a. | PMID[549498] |
NPT263 | Individual Protein | Muscarinic acetylcholine receptor M2 | Homo sapiens | Intrinsic activity | = | 1.0 | n.a. | PMID[549498] |
NPT420 | Individual Protein | Muscarinic acetylcholine receptor M3 | Cavia porcellus | PD2 | = | 7.1 | n.a. | PMID[549498] |
NPT420 | Individual Protein | Muscarinic acetylcholine receptor M3 | Cavia porcellus | Intrinsic activity | = | 1.0 | n.a. | PMID[549498] |
NPT420 | Individual Protein | Muscarinic acetylcholine receptor M3 | Cavia porcellus | PD2 | = | 5.69 | n.a. | PMID[549498] |
NPT263 | Individual Protein | Muscarinic acetylcholine receptor M2 | Homo sapiens | ED50 | = | 0.0037 | mg.kg-1 | PMID[549498] |
NPT262 | Individual Protein | Muscarinic acetylcholine receptor M1 | Homo sapiens | ED50 | = | 0.0025 | mg.kg-1 | PMID[549498] |
NPT263 | Individual Protein | Muscarinic acetylcholine receptor M2 | Homo sapiens | -Log ED50 | = | 6.42 | n.a. | PMID[549498] |
NPT263 | Individual Protein | Muscarinic acetylcholine receptor M2 | Homo sapiens | -Log KD | = | 4.61 | n.a. | PMID[549498] |
NPT263 | Individual Protein | Muscarinic acetylcholine receptor M2 | Homo sapiens | -Log KD | = | 4.7 | n.a. | PMID[549498] |
NPT420 | Individual Protein | Muscarinic acetylcholine receptor M3 | Cavia porcellus | -Log KD | = | 5.95 | n.a. | PMID[549498] |
NPT420 | Individual Protein | Muscarinic acetylcholine receptor M3 | Cavia porcellus | -Log KD | = | 4.62 | n.a. | PMID[549498] |
NPT263 | Individual Protein | Muscarinic acetylcholine receptor M2 | Homo sapiens | Relative affinity | = | 1.0 | n.a. | PMID[549498] |
NPT420 | Individual Protein | Muscarinic acetylcholine receptor M3 | Cavia porcellus | Relative affinity | = | 1.0 | n.a. | PMID[549498] |
NPT263 | Individual Protein | Muscarinic acetylcholine receptor M2 | Homo sapiens | Receptor occupied | = | 1.52 | % | PMID[549498] |
NPT263 | Individual Protein | Muscarinic acetylcholine receptor M2 | Homo sapiens | Receptor occupied | = | 1.01 | % | PMID[549498] |
NPT420 | Individual Protein | Muscarinic acetylcholine receptor M3 | Cavia porcellus | Receptor occupied | = | 6.62 | % | PMID[549498] |
NPT420 | Individual Protein | Muscarinic acetylcholine receptor M3 | Cavia porcellus | Receptor occupied | = | 7.85 | % | PMID[549498] |
NPT263 | Individual Protein | Muscarinic acetylcholine receptor M2 | Homo sapiens | pD2 | = | 6.69 | n.a. | PMID[549500] |
NPT263 | Individual Protein | Muscarinic acetylcholine receptor M2 | Homo sapiens | Intrinsic activity | = | 1.0 | n.a. | PMID[549500] |
NPT420 | Individual Protein | Muscarinic acetylcholine receptor M3 | Cavia porcellus | pD2 | = | 7.1 | n.a. | PMID[549500] |
NPT420 | Individual Protein | Muscarinic acetylcholine receptor M3 | Cavia porcellus | Intrinsic activity | = | 1.0 | n.a. | PMID[549500] |
NPT420 | Individual Protein | Muscarinic acetylcholine receptor M3 | Cavia porcellus | pD2 | = | 5.69 | n.a. | PMID[549500] |
NPT1301 | Individual Protein | Muscarinic acetylcholine receptor M2 | Rattus norvegicus | ED50 | = | 0.0037 | mg.kg-1 | PMID[549500] |
NPT263 | Individual Protein | Muscarinic acetylcholine receptor M2 | Homo sapiens | -Log ED50 | = | 6.42 | n.a. | PMID[549500] |
NPT263 | Individual Protein | Muscarinic acetylcholine receptor M2 | Homo sapiens | Relative efficacy | = | 1.0 | n.a. | PMID[549500] |
NPT420 | Individual Protein | Muscarinic acetylcholine receptor M3 | Cavia porcellus | Relative efficacy | = | 1.0 | n.a. | PMID[549500] |
NPT1301 | Individual Protein | Muscarinic acetylcholine receptor M2 | Rattus norvegicus | Ki | = | 75.0 | nM | PMID[549502] |
NPT1303 | Individual Protein | Muscarinic acetylcholine receptor M3 | Rattus norvegicus | Inhibition | = | 28.0 | % | PMID[549502] |
NPT432 | Individual Protein | Muscarinic acetylcholine receptor M4 | Rattus norvegicus | Ki | = | 1400.0 | nM | PMID[549502] |
NPT1301 | Individual Protein | Muscarinic acetylcholine receptor M2 | Rattus norvegicus | IC50 | = | 490.0 | nM | PMID[549502] |
NPT1301 | Individual Protein | Muscarinic acetylcholine receptor M2 | Rattus norvegicus | IC50 | = | 3900.0 | nM | PMID[549502] |
NPT432 | Individual Protein | Muscarinic acetylcholine receptor M4 | Rattus norvegicus | IC50 | = | 470.0 | nM | PMID[549502] |
NPT1303 | Individual Protein | Muscarinic acetylcholine receptor M3 | Rattus norvegicus | EC50 | = | 130.0 | nM | PMID[549502] |
NPT262 | Individual Protein | Muscarinic acetylcholine receptor M1 | Homo sapiens | Inhibition | = | 15.0 | % | PMID[549503] |
NPT263 | Individual Protein | Muscarinic acetylcholine receptor M2 | Homo sapiens | Ki | = | 75.0 | nM | PMID[549503] |
NPT265 | Individual Protein | Muscarinic acetylcholine receptor M4 | Homo sapiens | Ki | = | 28000.0 | nM | PMID[549503] |
NPT265 | Individual Protein | Muscarinic acetylcholine receptor M4 | Homo sapiens | Inhibition | = | 1.4 | % | PMID[549503] |
NPT263 | Individual Protein | Muscarinic acetylcholine receptor M2 | Homo sapiens | IC50 | = | 449.0 | nM | PMID[549503] |
NPT263 | Individual Protein | Muscarinic acetylcholine receptor M2 | Homo sapiens | IC50 | = | 3900.0 | nM | PMID[549503] |
NPT262 | Individual Protein | Muscarinic acetylcholine receptor M1 | Homo sapiens | Ki | = | 18197.01 | nM | PMID[549505] |
NPT263 | Individual Protein | Muscarinic acetylcholine receptor M2 | Homo sapiens | Ki | = | 489.78 | nM | PMID[549505] |
NPT210 | Individual Protein | Thyroid stimulating hormone receptor | Homo sapiens | Potency | = | 7943.3 | nM | PMID[549506] |
NPT64 | Individual Protein | ATPase family AAA domain-containing protein 5 | Homo sapiens | Potency | n.a. | 92.0 | nM | PMID[549507] |
NPT5 | Individual Protein | Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 | Homo sapiens | Potency | n.a. | 15848.9 | nM | PMID[549507] |
NPT104 | Individual Protein | Cerebroside-sulfatase | Homo sapiens | Potency | n.a. | 16944.1 | nM | PMID[549507] |
NPT95 | Individual Protein | Muscarinic acetylcholine receptor M1 | Rattus norvegicus | pD2 | = | 7.4 | n.a. | PMID[549494] |
NPT422 | Protein Family | Muscarinic acetylcholine receptor | Rattus norvegicus | Efficiency | = | 100.0 | % | PMID[549494] |
NPT95 | Individual Protein | Muscarinic acetylcholine receptor M1 | Rattus norvegicus | pD2 | = | 5.9 | n.a. | PMID[549494] |
NPT422 | Protein Family | Muscarinic acetylcholine receptor | Rattus norvegicus | IC50 | = | 12.0 | nM | PMID[549494] |
NPT95 | Individual Protein | Muscarinic acetylcholine receptor M1 | Rattus norvegicus | IC50 | = | 5680.0 | nM | PMID[549494] |
NPT95 | Individual Protein | Muscarinic acetylcholine receptor M1 | Rattus norvegicus | Ratio | = | 473.0 | n.a. | PMID[549494] |
NPT422 | Protein Family | Muscarinic acetylcholine receptor | Rattus norvegicus | Inhibition | = | 3.0 | % | PMID[549495] |
NPT422 | Protein Family | Muscarinic acetylcholine receptor | Rattus norvegicus | Ki | = | 14.0 | nM | PMID[549495] |
NPT2 | Others | Unspecified | Ratio | > | 10000.0 | n.a. | PMID[549495] | |
NPT422 | Protein Family | Muscarinic acetylcholine receptor | Rattus norvegicus | Ki | = | 4400.0 | nM | PMID[549495] |
NPT422 | Protein Family | Muscarinic acetylcholine receptor | Rattus norvegicus | Ki | = | 8.3 | nM | PMID[549495] |
NPT422 | Protein Family | Muscarinic acetylcholine receptor | Rattus norvegicus | Ratio | = | 530.0 | n.a. | PMID[549495] |
NPT938 | Organism | Cavia porcellus | Cavia porcellus | EC50 | = | 58.88 | nM | PMID[549496] |
NPT938 | Organism | Cavia porcellus | Cavia porcellus | EC50 | = | 31.62 | nM | PMID[549496] |
NPT2 | Others | Unspecified | ER | = | 331.0 | n.a. | PMID[549496] | |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | EC50 | = | 154.88 | nM | PMID[549496] |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | EC50 | = | 575.44 | nM | PMID[549496] |
NPT95 | Individual Protein | Muscarinic acetylcholine receptor M1 | Rattus norvegicus | K app | = | 28.0 | uM | PMID[549497] |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | EC50 | = | 169.82 | nM | PMID[549497] |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | FE | = | 1.1 | n.a. | PMID[549497] |
NPT1300 | Others | Muscarinic acetylcholine receptors; M1 & M2 | Homo sapiens | K app ratio | = | 0.082 | n.a. | PMID[549497] |
NPT938 | Organism | Cavia porcellus | Cavia porcellus | ED50 | = | 7.94 | n.a. | PMID[549499] |
NPT2 | Others | Unspecified | EPMR | = | 0.8 | n.a. | PMID[549499] | |
NPT2 | Others | Unspecified | ED50 | > | 5.0 | n.a. | PMID[549499] | |
NPT2 | Others | Unspecified | EPMR | > | 95.0 | n.a. | PMID[549499] | |
NPT95 | Individual Protein | Muscarinic acetylcholine receptor M1 | Rattus norvegicus | ED50 | = | 0.0025 | mg.kg-1 | PMID[549500] |
NPT938 | Organism | Cavia porcellus | Cavia porcellus | Kd | = | 19952.62 | nM | PMID[549500] |
NPT938 | Organism | Cavia porcellus | Cavia porcellus | Kd | = | 24547.09 | nM | PMID[549500] |
NPT938 | Organism | Cavia porcellus | Cavia porcellus | Kd | = | 1122.02 | nM | PMID[549500] |
NPT938 | Organism | Cavia porcellus | Cavia porcellus | Kd | = | 23988.33 | nM | PMID[549500] |
NPT938 | Organism | Cavia porcellus | Cavia porcellus | ED50 | = | 0.0000000794 | n.a. | PMID[549501] |
NPT2 | Others | Unspecified | Ratio | = | 0.4 | n.a. | PMID[549501] | |
NPT2 | Others | Unspecified | ED50 | > | 0.0005 | n.a. | PMID[549501] | |
NPT2 | Others | Unspecified | Ratio | > | 124.0 | n.a. | PMID[549501] | |
NPT2 | Others | Unspecified | Ratio | > | 6300.0 | n.a. | PMID[549501] | |
NPT95 | Individual Protein | Muscarinic acetylcholine receptor M1 | Rattus norvegicus | Inhibition | = | 3.0 | % | PMID[549502] |
NPT95 | Individual Protein | Muscarinic acetylcholine receptor M1 | Rattus norvegicus | Ki | = | 27.0 | nM | PMID[549502] |
NPT95 | Individual Protein | Muscarinic acetylcholine receptor M1 | Rattus norvegicus | Inhibition | = | 15.0 | % | PMID[549502] |
NPT95 | Individual Protein | Muscarinic acetylcholine receptor M1 | Rattus norvegicus | EC50 | = | 219.0 | nM | PMID[549502] |
NPT95 | Individual Protein | Muscarinic acetylcholine receptor M1 | Rattus norvegicus | Inhibition | = | 3.0 | % | PMID[549503] |
NPT95 | Individual Protein | Muscarinic acetylcholine receptor M1 | Rattus norvegicus | Ki | = | 27.0 | nM | PMID[549503] |
NPT95 | Individual Protein | Muscarinic acetylcholine receptor M1 | Rattus norvegicus | pD2 | = | 6.8 | n.a. | PMID[549504] |
NPT95 | Individual Protein | Muscarinic acetylcholine receptor M1 | Rattus norvegicus | Efficacy | = | 100.0 | % | PMID[549504] |
NPT95 | Individual Protein | Muscarinic acetylcholine receptor M1 | Rattus norvegicus | pD2 | = | 7.4 | n.a. | PMID[549504] |
NPT95 | Individual Protein | Muscarinic acetylcholine receptor M1 | Rattus norvegicus | Ki | = | 12.0 | nM | PMID[549504] |
NPT95 | Individual Protein | Muscarinic acetylcholine receptor M1 | Rattus norvegicus | Ki | = | 5680.0 | nM | PMID[549504] |
NPT95 | Individual Protein | Muscarinic acetylcholine receptor M1 | Rattus norvegicus | Potency | = | 2511.9 | nM | PMID[549506] |
NPT7 | Individual Protein | Thioredoxin reductase 1, cytoplasmic | Rattus norvegicus | Potency | n.a. | 23778.1 | nM | PMID[549507] |
☑ Note for Activity Records:
☉ The quantitative biological activities were primarily integrated from ChEMBL (Version-30) database and were also directly collected from PubMed literature. PubMed PMID was provided as the reference link for each activity record.
Top-200 similar NPs were calculated against the active-NP-set (includes 4,3285 NPs with experimentally-derived bioactivity available in NPASS)
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC293551 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
0.7288 | Intermediate Similarity | NPC275727 |
0.7164 | Intermediate Similarity | NPC473419 |
0.7164 | Intermediate Similarity | NPC475715 |
0.7164 | Intermediate Similarity | NPC475127 |
0.7121 | Intermediate Similarity | NPC59221 |
0.7077 | Intermediate Similarity | NPC233034 |
0.7015 | Intermediate Similarity | NPC266242 |
0.7015 | Intermediate Similarity | NPC254617 |
0.7015 | Intermediate Similarity | NPC171850 |
0.7015 | Intermediate Similarity | NPC306763 |
0.7015 | Intermediate Similarity | NPC74555 |
0.7015 | Intermediate Similarity | NPC474469 |
0.7 | Intermediate Similarity | NPC315806 |
0.6866 | Remote Similarity | NPC184150 |
0.6866 | Remote Similarity | NPC141156 |
0.6812 | Remote Similarity | NPC163538 |
0.6812 | Remote Similarity | NPC115800 |
0.6769 | Remote Similarity | NPC17455 |
0.6765 | Remote Similarity | NPC126664 |
0.6765 | Remote Similarity | NPC34291 |
0.6716 | Remote Similarity | NPC294883 |
0.6716 | Remote Similarity | NPC12514 |
0.6667 | Remote Similarity | NPC471419 |
0.6667 | Remote Similarity | NPC163134 |
0.6615 | Remote Similarity | NPC474014 |
0.6615 | Remote Similarity | NPC57846 |
0.6615 | Remote Similarity | NPC30126 |
0.6562 | Remote Similarity | NPC471421 |
0.6562 | Remote Similarity | NPC170172 |
0.6562 | Remote Similarity | NPC233364 |
0.6508 | Remote Similarity | NPC10262 |
0.6508 | Remote Similarity | NPC311668 |
0.6508 | Remote Similarity | NPC65832 |
0.6486 | Remote Similarity | NPC329077 |
0.6462 | Remote Similarity | NPC201338 |
0.6462 | Remote Similarity | NPC328786 |
0.6462 | Remote Similarity | NPC474627 |
0.6406 | Remote Similarity | NPC204709 |
0.64 | Remote Similarity | NPC325902 |
0.6364 | Remote Similarity | NPC62507 |
0.6364 | Remote Similarity | NPC8087 |
0.6338 | Remote Similarity | NPC475694 |
0.6338 | Remote Similarity | NPC473710 |
0.6324 | Remote Similarity | NPC474928 |
0.6316 | Remote Similarity | NPC150557 |
0.629 | Remote Similarity | NPC272396 |
0.6234 | Remote Similarity | NPC100204 |
0.6234 | Remote Similarity | NPC83248 |
0.622 | Remote Similarity | NPC52533 |
0.619 | Remote Similarity | NPC471442 |
0.619 | Remote Similarity | NPC471423 |
0.6154 | Remote Similarity | NPC471420 |
0.6111 | Remote Similarity | NPC327753 |
0.6111 | Remote Similarity | NPC327486 |
0.6111 | Remote Similarity | NPC223174 |
0.6102 | Remote Similarity | NPC81384 |
0.6061 | Remote Similarity | NPC76726 |
0.6061 | Remote Similarity | NPC193593 |
0.6061 | Remote Similarity | NPC143809 |
0.6061 | Remote Similarity | NPC290106 |
0.6032 | Remote Similarity | NPC178263 |
0.6032 | Remote Similarity | NPC277072 |
0.6 | Remote Similarity | NPC238646 |
0.6 | Remote Similarity | NPC471605 |
0.6 | Remote Similarity | NPC101746 |
0.6 | Remote Similarity | NPC165119 |
0.6 | Remote Similarity | NPC69798 |
0.6 | Remote Similarity | NPC77191 |
0.6 | Remote Similarity | NPC116377 |
0.6 | Remote Similarity | NPC471443 |
0.6 | Remote Similarity | NPC473952 |
0.5974 | Remote Similarity | NPC233108 |
0.5972 | Remote Similarity | NPC268922 |
0.5946 | Remote Similarity | NPC474468 |
0.5904 | Remote Similarity | NPC210456 |
0.5904 | Remote Similarity | NPC163352 |
0.5873 | Remote Similarity | NPC470664 |
0.5873 | Remote Similarity | NPC325180 |
0.5873 | Remote Similarity | NPC35816 |
0.5857 | Remote Similarity | NPC160661 |
0.5854 | Remote Similarity | NPC325723 |
0.5843 | Remote Similarity | NPC313821 |
0.5833 | Remote Similarity | NPC471418 |
0.5833 | Remote Similarity | NPC328806 |
0.5823 | Remote Similarity | NPC70574 |
0.5811 | Remote Similarity | NPC137554 |
0.5811 | Remote Similarity | NPC299603 |
0.5811 | Remote Similarity | NPC255535 |
0.5811 | Remote Similarity | NPC476694 |
0.5811 | Remote Similarity | NPC476695 |
0.5811 | Remote Similarity | NPC476696 |
0.5811 | Remote Similarity | NPC285014 |
0.5811 | Remote Similarity | NPC28959 |
0.5806 | Remote Similarity | NPC27359 |
0.5806 | Remote Similarity | NPC295832 |
0.5806 | Remote Similarity | NPC198398 |
0.5806 | Remote Similarity | NPC224624 |
0.5802 | Remote Similarity | NPC93630 |
0.5797 | Remote Similarity | NPC306462 |
0.5797 | Remote Similarity | NPC69669 |
0.5797 | Remote Similarity | NPC2432 |
0.5797 | Remote Similarity | NPC150680 |
0.5797 | Remote Similarity | NPC22774 |
0.5797 | Remote Similarity | NPC218150 |
0.5783 | Remote Similarity | NPC43246 |
0.5783 | Remote Similarity | NPC89051 |
0.5781 | Remote Similarity | NPC270041 |
0.5775 | Remote Similarity | NPC303798 |
0.5775 | Remote Similarity | NPC286851 |
0.5775 | Remote Similarity | NPC315980 |
0.5769 | Remote Similarity | NPC314968 |
0.5769 | Remote Similarity | NPC314772 |
0.5758 | Remote Similarity | NPC8979 |
0.5732 | Remote Similarity | NPC112842 |
0.5732 | Remote Similarity | NPC71339 |
0.5714 | Remote Similarity | NPC190334 |
0.5714 | Remote Similarity | NPC306838 |
0.5714 | Remote Similarity | NPC62927 |
0.5714 | Remote Similarity | NPC3094 |
0.5696 | Remote Similarity | NPC316807 |
0.5696 | Remote Similarity | NPC98750 |
0.5694 | Remote Similarity | NPC322801 |
0.5694 | Remote Similarity | NPC129100 |
0.5694 | Remote Similarity | NPC291650 |
0.5692 | Remote Similarity | NPC471917 |
0.5679 | Remote Similarity | NPC271772 |
0.5679 | Remote Similarity | NPC81006 |
0.5679 | Remote Similarity | NPC288415 |
0.5679 | Remote Similarity | NPC31313 |
0.5679 | Remote Similarity | NPC45906 |
0.5679 | Remote Similarity | NPC36927 |
0.5679 | Remote Similarity | NPC319753 |
0.5679 | Remote Similarity | NPC149908 |
0.566 | Remote Similarity | NPC227267 |
0.5645 | Remote Similarity | NPC82512 |
0.5634 | Remote Similarity | NPC75435 |
0.5634 | Remote Similarity | NPC142290 |
0.5634 | Remote Similarity | NPC198341 |
0.5634 | Remote Similarity | NPC471780 |
0.5634 | Remote Similarity | NPC471892 |
0.5634 | Remote Similarity | NPC223386 |
0.5632 | Remote Similarity | NPC476019 |
0.5625 | Remote Similarity | NPC123814 |
0.5616 | Remote Similarity | NPC316445 |
0.561 | Remote Similarity | NPC106780 |
0.56 | Remote Similarity | NPC114640 |
0.56 | Remote Similarity | NPC170963 |
0.56 | Remote Similarity | NPC169976 |
0.56 | Remote Similarity | NPC33267 |
0.56 | Remote Similarity | NPC126366 |
0.56 | Remote Similarity | NPC324165 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC293551 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
0.7077 | Intermediate Similarity | NPD9440 | Discontinued |
0.7 | Intermediate Similarity | NPD9653 | Clinical (unspecified phase) |
0.6984 | Remote Similarity | NPD9240 | Approved |
0.6984 | Remote Similarity | NPD9239 | Approved |
0.6875 | Remote Similarity | NPD393 | Approved |
0.6842 | Remote Similarity | NPD883 | Phase 2 |
0.6842 | Remote Similarity | NPD882 | Phase 2 |
0.6765 | Remote Similarity | NPD9443 | Clinical (unspecified phase) |
0.6719 | Remote Similarity | NPD9455 | Approved |
0.6712 | Remote Similarity | NPD372 | Clinical (unspecified phase) |
0.6575 | Remote Similarity | NPD9407 | Approved |
0.6567 | Remote Similarity | NPD1457 | Discontinued |
0.6522 | Remote Similarity | NPD9444 | Discontinued |
0.6389 | Remote Similarity | NPD9405 | Approved |
0.6349 | Remote Similarity | NPD9659 | Approved |
0.6282 | Remote Similarity | NPD2691 | Clinical (unspecified phase) |
0.6234 | Remote Similarity | NPD9429 | Discontinued |
0.6176 | Remote Similarity | NPD9211 | Clinical (unspecified phase) |
0.6119 | Remote Similarity | NPD9022 | Phase 2 |
0.6119 | Remote Similarity | NPD9024 | Phase 2 |
0.6111 | Remote Similarity | NPD9445 | Approved |
0.6102 | Remote Similarity | NPD9463 | Phase 3 |
0.6102 | Remote Similarity | NPD9462 | Approved |
0.6 | Remote Similarity | NPD6943 | Clinical (unspecified phase) |
0.5949 | Remote Similarity | NPD9558 | Phase 3 |
0.5873 | Remote Similarity | NPD9660 | Approved |
0.5846 | Remote Similarity | NPD6950 | Discontinued |
0.5843 | Remote Similarity | NPD3189 | Approved |
0.5843 | Remote Similarity | NPD3190 | Approved |
0.5843 | Remote Similarity | NPD3191 | Approved |
0.5806 | Remote Similarity | NPD9226 | Approved |
0.5806 | Remote Similarity | NPD9225 | Phase 3 |
0.5797 | Remote Similarity | NPD9028 | Phase 2 |
0.5797 | Remote Similarity | NPD9026 | Phase 2 |
0.5797 | Remote Similarity | NPD9029 | Phase 3 |
0.5797 | Remote Similarity | NPD9027 | Phase 3 |
0.5789 | Remote Similarity | NPD9457 | Approved |
0.5789 | Remote Similarity | NPD9456 | Approved |
0.5783 | Remote Similarity | NPD9581 | Clinical (unspecified phase) |
0.5783 | Remote Similarity | NPD9580 | Clinical (unspecified phase) |
0.5769 | Remote Similarity | NPD9435 | Approved |
0.5769 | Remote Similarity | NPD9434 | Approved |
0.5765 | Remote Similarity | NPD755 | Phase 3 |
0.575 | Remote Similarity | NPD9556 | Approved |
0.5733 | Remote Similarity | NPD6704 | Discontinued |
0.5732 | Remote Similarity | NPD280 | Approved |
0.5714 | Remote Similarity | NPD11 | Approved |
0.5714 | Remote Similarity | NPD1760 | Approved |
0.5714 | Remote Similarity | NPD9604 | Approved |
0.5714 | Remote Similarity | NPD376 | Approved |
0.5714 | Remote Similarity | NPD9603 | Phase 3 |
0.5714 | Remote Similarity | NPD9602 | Phase 3 |
0.5694 | Remote Similarity | NPD9031 | Approved |
0.5694 | Remote Similarity | NPD9032 | Approved |
0.5694 | Remote Similarity | NPD9030 | Approved |
0.5694 | Remote Similarity | NPD9033 | Approved |
0.5679 | Remote Similarity | NPD9561 | Approved |
0.5679 | Remote Similarity | NPD9560 | Approved |
0.5679 | Remote Similarity | NPD9573 | Phase 2 |
0.5672 | Remote Similarity | NPD9657 | Discontinued |
0.5634 | Remote Similarity | NPD4272 | Discontinued |
0.5625 | Remote Similarity | NPD3215 | Phase 1 |
0.561 | Remote Similarity | NPD9546 | Phase 2 |
0.561 | Remote Similarity | NPD9559 | Phase 1 |
Bioactivity similarity was calculated based on bioactivity descriptors of compounds. The bioactivity descriptors were calculated by a recently developed AI algorithm Chemical Checker (CC) [Nature Biotechnology, 38:1087–1096, 2020; Nature Communications, 12:3932, 2021], which evaluated bioactivity similarities at five levels:
☉ A: chemistry similarity;
☉ B: biological targets similarity;
☉ C: networks similarity;
☉ D: cell-based bioactivity similarity;
☉ E: similarity based on clinical data.
Those 5 categories of CC bioactivity descriptors were calculated and then subjected to manifold projection using UMAP algorithm, to project all NPs on a 2-Dimensional space. The current NP was highlighted with a small circle in the 2-D map. Below figures: left-to-right, A-to-E.